Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS107 vs Investigator's Choice in Advanced CLDN18.2-Positive Gastric or GEJ Adenocarcinoma
NCT07284134Phase 3Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of JS107 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Progression-Free Survival (BICR-assessed) up to 2 years and Overall Survival up to 5 years. Started Dec 2025; status: recruiting.
02
Drugs
JS107
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07284134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284134.